Edwin M. Posadas

8.8k total citations
173 papers, 5.6k citations indexed

About

Edwin M. Posadas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Edwin M. Posadas has authored 173 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 53 papers in Cancer Research. Recurrent topics in Edwin M. Posadas's work include Prostate Cancer Treatment and Research (84 papers), Cancer Genomics and Diagnostics (31 papers) and Renal cell carcinoma treatment (26 papers). Edwin M. Posadas is often cited by papers focused on Prostate Cancer Treatment and Research (84 papers), Cancer Genomics and Diagnostics (31 papers) and Renal cell carcinoma treatment (26 papers). Edwin M. Posadas collaborates with scholars based in United States, Canada and Italy. Edwin M. Posadas's co-authors include Robert A. Figlin, Hsian‐Rong Tseng, Elise C. Kohn, Leland W.K. Chung, Neil A. Bhowmick, Michael R. Freeman, Ravi Salgia, Seth M. Steinberg, Valentina R. Minciacchi and Yi‐Tsung Lu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Advanced Materials and Journal of Clinical Investigation.

In The Last Decade

Edwin M. Posadas

165 papers receiving 5.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edwin M. Posadas United States	41	2.7k	1.9k	1.9k	1.9k	611	173	5.6k
Stephen R. Wedge United Kingdom	39	3.6k 1.3×	2.6k 1.4×	1.6k 0.8×	1.4k 0.8×	452 0.7×	103	7.0k
Michail Ignatiadis Belgium	40	2.3k 0.8×	3.8k 2.0×	1.5k 0.8×	3.8k 2.0×	467 0.8×	128	6.6k
Steven Van Laere Belgium	45	2.6k 1.0×	2.7k 1.4×	968 0.5×	2.5k 1.3×	332 0.5×	161	5.6k
Glen J. Weiss United States	44	4.2k 1.6×	3.1k 1.6×	1.9k 1.0×	1.9k 1.0×	349 0.6×	209	7.9k
Olivier Trédan France	39	2.2k 0.8×	4.4k 2.3×	2.4k 1.3×	1.7k 0.9×	739 1.2×	234	7.8k
Mustafa Khasraw Australia	34	1.7k 0.6×	2.3k 1.2×	1.5k 0.8×	1.3k 0.7×	570 0.9×	194	5.8k
Peter Vermeulen Belgium	42	3.1k 1.1×	3.2k 1.7×	1.1k 0.6×	2.7k 1.4×	361 0.6×	142	6.6k
Brigitte Rack Germany	37	1.9k 0.7×	4.6k 2.4×	1.5k 0.8×	3.7k 2.0×	784 1.3×	218	6.6k
Arnulf Mayer Germany	26	2.1k 0.8×	1.1k 0.6×	772 0.4×	2.8k 1.5×	867 1.4×	63	5.2k
Rafael López‐López Spain	35	1.8k 0.7×	2.2k 1.1×	934 0.5×	1.7k 0.9×	460 0.8×	242	4.5k

Countries citing papers authored by Edwin M. Posadas

Since Specialization

Citations

This map shows the geographic impact of Edwin M. Posadas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin M. Posadas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin M. Posadas more than expected).

Fields of papers citing papers by Edwin M. Posadas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edwin M. Posadas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin M. Posadas. The network helps show where Edwin M. Posadas may publish in the future.

Co-authorship network of co-authors of Edwin M. Posadas

This figure shows the co-authorship network connecting the top 25 collaborators of Edwin M. Posadas. A scholar is included among the top collaborators of Edwin M. Posadas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edwin M. Posadas. Edwin M. Posadas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luu, Michael, Rebecca Gale, Leslie K. Ballas, et al.. (2024). Variation in content discussed by specialty in consultations for clinically localized prostate cancer. Urologic Oncology Seminars and Original Investigations. 42(9). 288.e7–288.e15.

Posadas, Edwin M., et al.. (2024). Applications of wearable activity monitors for prostate cancer survivors: A systematic scoping review. Contemporary Clinical Trials. 143. 107563–107563. 3 indexed citations

Morgan, Todd M., Stephen A. Boorjian, Mark K. Buyyounouski, et al.. (2024). Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. The Journal of Urology. 211(4). 526–532. 13 indexed citations

Majlessipour, Fataneh, et al.. (2023). Characterization of pre-malignant lesions in patients with pediatric neurofibromatosis type 1 using a novel whole-body magnetic resonance imaging technique.. Journal of Clinical Oncology. 41(16_suppl). TPS10637–TPS10637.

Kim, Kyung, Edwin M. Posadas, Kevin S. Scher, et al.. (2023). System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.. Journal of Clinical Oncology. 41(16_suppl). 1600–1600. 1 indexed citations

Marshall, Catherine H., Wei Fu, Hao Wang, et al.. (2021). Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 27(6). 1623–1630. 39 indexed citations

Dorff, Tanya B., Cy A. Stein, Marcin Kortylewski, et al.. (2020). Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals. 35(7). 485–489. 3 indexed citations

Freedland, Stephen J., Taofik Oyekunle, Andrew J. Armstrong, et al.. (2020). A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). Clinical Cancer Research. 26(12). 3035–3043. 40 indexed citations

Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2020). Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research. 26(14). 3517–3524. 12 indexed citations

10.

Mishra, Rajeev, Subhash Haldar, Veronica R. Placencio, et al.. (2018). Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. Journal of Clinical Investigation. 128(10). 4472–4484. 124 indexed citations

11.

Reis-Sobreiro, Mariana, Jie‐Fu Chen, Tatiana Novitskaya, et al.. (2018). Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. Cancer Research. 78(21). 6086–6097. 53 indexed citations

12.

Salem, Ahmed F., Si Wang, Sandrine Billet, et al.. (2018). Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate. Journal of Medicinal Chemistry. 61(5). 2052–2061. 56 indexed citations

13.

Minciacchi, Valentina R., Cristiana Spinelli, Mariana Reis-Sobreiro, et al.. (2017). MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. Cancer Research. 77(9). 2306–2317. 120 indexed citations

14.

Howard, Lauren E., Christopher L. Amling, William J. Aronson, et al.. (2015). Is computed tomography a necessary part of a metastatic evaluation for castration‐resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 122(2). 222–229. 6 indexed citations

15.

Josson, Sajni, Murali Gururajan, Peizhen Hu, et al.. (2014). miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer. Clinical Cancer Research. 20(17). 4636–4646. 118 indexed citations

16.

Gururajan, Murali, Sajni Josson, Gina Chia‐Yi Chu, et al.. (2014). miR-154* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer. Clinical Cancer Research. 20(24). 6559–6569. 82 indexed citations

17.

Zhao, Libo, Yi‐Tsung Lu, Fuqiang Li, et al.. (2013). High‐Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber‐Embedded Microchip for Whole Exome Sequencing. Advanced Materials. 25(21). 2897–2902. 133 indexed citations

18.

Liao, Chuanhong, Jinlu Dai, Evan T. Keller, et al.. (2011). Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells. Clinical Cancer Research. 17(10). 3112–3122. 28 indexed citations

19.

Szmulewitz, Russell Z., Supriya G. Mohile, Edwin M. Posadas, et al.. (2009). A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. European Urology. 56(1). 97–104. 54 indexed citations

20.

Dahut, William L., Charity D. Scripture, Edwin M. Posadas, et al.. (2008). A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Clinical Cancer Research. 14(1). 209–214. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact